Enzorab 20 Tablet contains Rabeprazole 20 mg, a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. It is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and peptic ulcer disease, including duodenal and gastric ulcers. Rabeprazole facilitates healing of acid-related mucosal damage and provides symptomatic relief from heartburn, acid regurgitation, and epigastric pain. The drug demonstrates a rapid onset of action with a prolonged duration, allowing once-daily dosing for most indications. Enzorab 20 is generally well-tolerated; common adverse effects may include headache, diarrhea, nausea, abdominal pain, and flatulence. It is contraindicated in patients with known hypersensitivity to Rabeprazole or other PPIs. Caution is advised when co-administered with drugs metabolized by cytochrome P450 enzymes due to potential drug interactions. Long-term use requires monitoring for possible vitamin B12 deficiency and magnesium imbalance. Enzorab 20 should be taken orally, preferably before meals, as directed by a healthcare professional to ensure optimal therapeutic outcomes in acid-related gastrointestinal disorders.